CHINA PHARMA HOLDINGS, INC.

Regulatory Filings • May 30, 2024

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 23, 2024

Field: Rule-Page

Field: /Rule-Page

CHINA PHARMA HOLDINGS, INC.

(Exact name of Registrant as specified in charter)

Nevada	001-34471	73-1564807
(State or other jurisdiction	(Commission File No.)	(IRS Employer
of Incorporation)		Identification No.)

Second Floor , No. 17, Jinpan Road

Haikou , Hainan Province , China 570216

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: + 86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐ Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CPHI	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1.01. Entry into a Material Definitive Agreement.

On May 23, 2024, China Pharma Holdings, Inc. (the “Company”) entered into an Amendment No. 2 (the “Second Amendment”), to the Convertible Promissory Note dated November 17, 2021 and its Amendment No.1 dated April 13, 2023 (collectively, the “Note”). The Company originally issued the Note to Streeterville Capital, LLC (the “Note Holder”) pursuant to a Securities Purchase Agreement dated November 17, 2021.

The Note Holder and the Company have agreed, according to the terms of the Second Amendment, to extend the maturity date of the Note to August 19, 2025. In consideration of the extension, the Company has agreed to pay to the Note Holder an extension fee equal to two percent (2%) of the outstanding balance of the Note (“Extension Fee”), and lower the minimum monthly redemption amount from the outstanding balance of the Note that the Company is obligated to redeem from $150,000 to $37,182.33. The Second Amendment also includes customary representations and warranties by the Company. The outstanding balance of the Note as of May 23, 2024, following the application of the Extension Fee, is $557,735.00. The outstanding balance of the Note on November 19, 2021, when the Note was originally issued, was $5,250,000.00, including an original issue discount of $250,000.00.

The foregoing description is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 hereto, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following is filed as an exhibit to this report:

Exhibit Number	Exhibit
10.1	Amendment #2 to Convertible Promissory Note dated May 23, 2024
104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 30, 2024

CHINA PHARMA HOLDINGS, INC.
By:	/s/ Zhilin Li
Name:	Zhilin Li
Title:	President and Chief Executive Officer

2

Field: Rule-Page

Field: /Rule-Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjV0KwjAQhE/QOyx5lv4EReyjRUWsIkXE12hXCbbZsolVj+QtTVvEZWFZZr4ZIUZiRUtdIcNpXuRwwLqplEMo8IqM5oLeka03Kfhb4E1bx8q4/v2BGXkGPTMJpTx7obe22mKZQjyJ5CySY0iSNJ7CfiuCTs/IXHWJxmlVgTIl7Jka1ugUv4eEg3qRofrdVx2RrSaTQhLGg/wBGScSdtSqJ/HdQp5nIhj1E4gV06PxrsXLoelIWFRY+zo70P8Nvgn/SpI=